Rayner Molly, Brose Kelsey
Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
Department of Oncology, University of Saskatchewan, Saskatoon, SK, Canada.
J Hematol. 2024 Jun;13(3):125-127. doi: 10.14740/jh1278. Epub 2024 Jun 28.
Hereditary protein S (PS) deficiency is a rare condition associated with increased risk of venous thromboembolism (VTE). In 2020, the coronavirus disease 2019 (COVID-19) pandemic prompted development of vaccinations to protect against the virus. PS deficiency is not a contraindication to COVID-19 vaccinations, but there are no studies regarding potential adverse effects in this population. We report two cases, a 43-year-old mother and her 18-year-old son, who developed VTE shortly after their first COVID-19 vaccines. Testing confirmed hereditary PS deficiency with a previously undescribed mutation in both cases. The temporal association between COVID-19 vaccination and VTE in these patients with hereditary PS deficiency suggests a potential causal relationship. However, it is unclear if this applies to all patients with hereditary PS deficiency. This highlights the importance of reporting adverse events following COVID-19 vaccinations in this population to evaluate the risks and benefits of vaccination.
遗传性蛋白S（PS）缺乏症是一种罕见疾病，与静脉血栓栓塞（VTE）风险增加相关。2020年，2019冠状病毒病（COVID-19）大流行促使人们研发疫苗以预防该病毒。PS缺乏症并非COVID-19疫苗接种的禁忌证，但尚无关于该人群潜在不良反应的研究。我们报告两例病例，一名43岁母亲及其18岁儿子，他们在接种第一剂COVID-19疫苗后不久发生了VTE。检测证实两例均存在遗传性PS缺乏症且伴有一种此前未描述的突变。在这些遗传性PS缺乏症患者中，COVID-19疫苗接种与VTE之间的时间关联提示可能存在因果关系。然而，尚不清楚这是否适用于所有遗传性PS缺乏症患者。这凸显了报告该人群COVID-19疫苗接种后不良事件以评估疫苗接种风险和益处的重要性。
